| Old Articles: <Older 2741-2750 Newer> |
|---|
 |
Pharmaceutical Executive
March 1, 2006
Alana Klein |
Alternative Media: Masters of Their Domain The entire medical community - physicians, hospitals, medical associations, medical students and residents, pharma and medical device companies, and patient groups - are taking advantage of the .md domain.   |
Pharmaceutical Executive
March 1, 2006
Jeff Brady |
Sales Management: Spending Under Scrutiny Five states have already mandated that drug companies track, control, and report their marketing and sales spend directed at healthcare professionals, and many more states have legislation pending with distinct requirements. |
Pharmaceutical Executive
March 1, 2006
Lou Morris |
Backpage: Warning Letter A press release describes the existence of a new Patient Counseling Information section. Drug labels have contained a patient information section within the precautions section. The suggestion that this section is new is false and misleading. |
Pharmaceutical Executive
March 1, 2006
Jill Wechsler |
Washington Report: Labels and Liability New FDA guidance aims at better communication of risks. But it creates some, too. |
Pharmaceutical Executive
March 1, 2006
Patrick Clinton |
From the Editor: Fine Whines What's wrong with so much of what passes as criticism of science, healthcare, and pharma these days isn't criticism at all. It's just whining. |
Pharmaceutical Executive
March 1, 2006
Breitstein & Clinton |
Market Research Roundtable A group of top market researchers to discuss the issues shaping an evolving pharmaceuticals industry. |
Pharmaceutical Executive
March 1, 2006
Sarah Houlton |
Global Report: Chemicals Legislation in Europe Chemicals legislation in Europe may affect pharma's relationship with suppliers. |
Pharmaceutical Executive
March 1, 2006
Joanna Breitstein |
Thought Leader: Q&A with Hugo Stephenson Hugo Stephenson, president of Quintiles' Strategic Research Services, offers insight into the struggles the pharmaceutical industry faces, and the solutions they're finding, to financing post-approval clinical trials. |
Pharmaceutical Executive
March 1, 2006
Blair Gibson |
Finance: Promotional Productivity What drugs are cash traps? The truth is, most companies don't know. But a product portfolio analysis can reveal where resources are best directed - and where it's time to pull the plug. |
Pharmaceutical Executive
March 1, 2006
James McDonald, Jr. |
Legal: Hey, Good Lookin': Sex Discrimination in Hiring Reps Hiring beautiful drug reps might be good for business, but it also might be challenged as discrimination in a court of law. |
| <Older 2741-2750 Newer> Return to current articles. |
